Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Tohoku Medical and Pharmaceutical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetes patients who are scheduled to be admitted to the Tohoku Medical and Pharmaceutical University Hospital 2) Patients who are taking the following doses of SGLT2 inhibitor containing preparations once a day in the morning at the time of admission Ipragliflozin 50mg/day or 100mg/day Tofogliflozin 20mg/day Dapagliflozin 5mg/day or 10mg/day Canagliflozin 100mg/day Empagliflozin 10mg/day or 25mg/day Luseogliflozin 2.5mg/day or 5mg/day 3) Patients who plan to discontinue the above SGLT2 inhibitors after admission 4) written informed consent
Exclusion criteria
Exclusion criteria: 1) Pregnancy 2) Patients who require adjustment of oral steroid dosage during our study period 3) eGFR < 45mL/min/1.73m2 4) Patients who discontinued SGLT2 inhibitors before hospitalization 5) Patients who are inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of days until urinary glucose excretion becomes equivalent to the period without SGLT2 inhibitor administration after discontinuation of a SGLT2 inhibitor administration | — |
Secondary
| Measure | Time frame |
|---|---|
| (If two or more types of SGLT2 inhibitors were discontinued) Number of days to disappearance of urinary glucose excretion for each drug, percentage of urinary glucose disappearance within 3 days after hospitalization, urinary glucose disappearance rate, number of days until blood ketone bodies are equivalent to the period without SGLT2 inhibitor administration | — |
Countries
Japan
Contacts
Public ContactYuichiro Munakata
Tohoku Medical and Pharmaceutical University Division of Diabetes, Metabolism and Endocrinology
Outcome results
None listed